Results 231 to 240 of about 118,446 (304)

Implementation and evaluation of a pragmatic community streptococcal treatment programme to improve rheumatic heart disease primary prevention in Uganda. [PDF]

open access: yesBMJ Glob Health
Ndagire E   +18 more
europepmc   +1 more source

Mesenchymal stromal cell therapy for rheumatoid arthritis: Long‐term efficacy, safety, and mechanistic insights

open access: yesRheumatology &Autoimmunity, EarlyView.
Graphical abstract summarizing the multifactorial pathogenesis of rheumatoid arthritis (RA) and the therapeutic potential of mesenchymal stromal cell (MSC) therapy. MSCs provide promising benefits through their immunomodulatory properties, low immunogenicity, ability to promote tissue repair, and multi‐lineage differentiation, presenting a potential ...
Yingjia Chen   +6 more
wiley   +1 more source

Age‐related clinical heterogeneity and peripheral T cell profile alterations in primary Sjögren's disease: A retrospective study of 5778 patients

open access: yesRheumatology &Autoimmunity, EarlyView.
This large‐scale retrospective study of 5778 primary Sjögren's disease (SjD) patients, stratified by diagnostic age, defines a distinct clinical and immunological profile for early‐diagnosed (<45 years) disease. We identified early diagnosis as an independent risk factor for hypergammaglobulinemia and interstitial lung disease, underpinned by a ...
Yuan Ning   +7 more
wiley   +1 more source

The economic burden of rheumatic heart disease in the Eastern Mediterranean Region. [PDF]

open access: yesBMJ Glob Health
Elmusharaf K   +8 more
europepmc   +1 more source

The evolving role of regulatory T cells in Sjögren's disease pathogenesis and the promise of Treg‐based therapies: A comprehensive review

open access: yesRheumatology &Autoimmunity, EarlyView.
Graphical Abstract The evolving role of regulatory T cells in primary Sjögren's disease pathogenesis and the promise of Treg‐based therapies. Abstract Sjögren's disease (SjD) is a chronic systemic autoimmune disorder characterised by exocrine gland dysfunction and diverse systemic manifestations.
Gagan Urs   +5 more
wiley   +1 more source

Impact of biological/targeted versus conventional synthetic disease‐modifying antirheumatic drugs on patient‐reported outcomes in rheumatoid arthritis

open access: yesRheumatology &Autoimmunity, EarlyView.
Patient‐reported outcomes (PROs) were compared among rheumatoid arthritis patients who maintained low disease activity or remission for at least 6 months based on the disease‐modifying antirheumatic drug (DMARD)administered. Even with comparable disease activity, methotrexate (MTX) group, biological/targeted synthetic DMARDs (b/tsDMARDs), particularly ...
Masafumi Sugiyama   +4 more
wiley   +1 more source

Prevalence of Rheumatic Heart Disease Among School-Aged Children in Low- and Middle-Income Countries: A Systematic Review and Meta-Analysis. [PDF]

open access: yesCureus
Okorie MA   +11 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy